ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Approach to determining VWD subtype

Approach to determining VWD subtype
Diagnosis of VWD includes both clinical and laboratory features. After determining whether VWD is present (refer to separate algorithm in UpToDate), one then determines the subtype, which has implications for management, as depicted here. Type 1 is the most common, affecting 75 to 85% of individuals. Type 2A affects approximately 10 to 15% of individuals and type 2B affects approximately 5%. Types 2M and 2N are less common, and type 3 is rare. The bleeding history, family history, and inheritance pattern are also important factors in making the diagnosis of VWD and in assigning the type. Screening may be performed by the primary clinician or hematologist. Secondary testing is generally done by the consulting hematologist or clinician with expertise in diagnosing VWD.

VWD: von Willebrand disease; VWF: von Willebrand factor; VWF:Ag: von Willebrand factor antigen; FVIII: factor VIII; RIPA: ristocetin-induced platelet aggregation.

* VWF activity is measured using one of several assays including:
  • VWF:RCo – Ristocetin cofactor activity (binding to platelet GPIb in the presence of ristocetin)
  • VWF:GPIbR – Binding to recombinant GPIb in the presence of ristocetin
  • VWF:GPIbM – Binding to recombinant mutated (gain-of-function) GPIb that does not require ristocetin
In rare cases where VWD is suspected, VWF activity is >50%, and factor VIII activity is <30%, additional testing is needed to distinguish type 2N VWD from mild hemophilia. Refer to inset box for details.

¶ Less commonly, cases of type 2B may have a normal multimer distribution.

Graphic 131040 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟